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Renal allograft recipients with high susceptibility to
cutaneous malignancy have an increased prevalence of
human papillomavirus DNA in skin tumours and a
greater risk of anogenital malignancy
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Summary Renal allograft recipients (RARs) have a well-documented increased incidence of viral warts and cutaneous neoplasia, particularly
those with long graft life and high sun exposure. A clinicopathological survey of 69 RARs in south-east Scotland, with follow-up periods of up
to 28 years after transplantation, revealed marked variation in patient susceptibility to cutaneous malignancy with concomitant variation in
HPV prevalence. Skin cancers were found in 34 patients. Eight patients showed high susceptibility [defined as more than four intraepidermal
carcinomas (IECs) or invasive squamous cell carcinomas (SCCs)] 42 had intermediate susceptibility (1-3 IECs or SCCs, or >3 keratoses)
and 18 had low susceptibility (<3 keratoses and no cancers). SCCs, IECs and keratoses from the high-susceptibility group were found to have
greater prevalences of human papillomavirus (HPV) DNA (56%, 45% and 50% respectively), than SCCs (0%) and IECs (33%) from
intermediate-susceptibility RARs and keratoses (36%) from the combined intermediate- and low-susceptibility groups and compared with
a group of immunocompetent controls (27%, 20% and 15% respectively). No differences in p53 protein accumulation, determined immuno-
histochemically, were observed in tumours from the three groups. Categorization of RARs by susceptibility to cutaneous malignancy provides
clinically useful information, as significantly more high-susceptibility patients (38%) developed aggressive, potentially lethal anogenital or
cutaneous squamous cell cancers than did patients in the intermediate group (5%, P=0.005) or the low-susceptibility group (0%).
Keywords: renal allograft recipient; human papillomavirus; keratoses; intraepidermal carcinoma; squamous cell carcinoma; viral wart; skin
neoplasia; Southern hybridization; polymerase chain reaction; p53; immunocytochemistry
Renal allograft recipients (RARs) receive immunosuppressive
therapy over long periods oftime and have an increased incidence
of cutaneous neoplasia, particularly those with a long graft life or
high sun exposure (Arends et al, 1990; Benton and Arends, 1996).
Allograft recipients (mainly women) are especially susceptible to
human papillomavirus (HPV)-related anogenital tract neoplasia,
which may be life-threatening (Alloub et al, 1989). The skin
neoplasms form part of a spectrum, encompassing viral warts
showing dysplasia, actinic or verrucous keratoses displaying
various viral architectural features or epidermal dysplasia and
sometimes in topographical continuity with intraepidermal carci-
noma (IEC) and invasive squamous cell carcinoma (SCC)
(Blessing et al, 1989). In contrast to anogenital cancers, 70-80% of
which contain HPV 16 or 18 DNA, and to the skin cancers
seen in epidermodysplasia verruciformis (EV), 90% of which
contain HPV 5 or 8 DNA (Orth, 1987; Arends et al, 1990, 1993;
Pfister, 1992), the results of HPV DNA detection studies
in cutaneous SCCs from RARs show little consistency either in
the frequency or viral type of HPV DNA found (Benton and
Arends, 1996). Some of this variation may be explained by small
size of study sample or differences in substrates and techniques
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used, i.e. fresh or frozen tissue vs formalin-fixed paraffin-processed
tissue (associated with poorer quality ofextracted DNA,particularly
for amplification of longer DNA fragments) (Wright and Manos,
1990), dotblotting vs Southern hybridization orPCRtechniques and,
finally, the different ranges ofHPV probes or PCRprimers used.
Early studies were small and focused on HPV types 5 and 8 to
determine whether skin cancers of RARs resembled those of EV
patients. These studies reported the detection of HPV 5 and 8 in
small numbers ofcases that often included highly selected individ-
uals, such as patients with multiple SCCs (Lutzner et al, 1980,
1983; Van der Leest et al, 1987; Barr et al, 1989; Blessing et al,
1990). Negative results were reported in a number of studies;
many are explicable by the use of less than ideal substrates, such
as DNA from formalin-fixed tissue or suboptimal techniques, such
as reverse blotting or dot-blot hybridization (Rudlinger and Grob,
1989; Blessing et al, 1990; Dyall-Smith et al, 1991; Smith et al,
1993; McGregor et al, 1994), orthe use ofPCR with LI consensus
primers that were designed primarily for detection of anogenital
rather than cutaneous HPV types. These factors may account for
negative results when looking for low copy numbers ofcutaneous
and EV types ofHPV DNA using poor-quality substrate.
Recently, more sensitive techniques have detected a wide
variety of HPV types, including uncharacterized HPV types, in
skin cancers from RARs. In situ hybridization, Southern hybridiza-
tion and PCR techniques detected HPV DNA in 37-54% SCCs
from RARs, including anogenital, cutaneous and EV types of
HPV (Muller et al, 1989; Eliezri et al, 1990; Euvrard et al, 1991;
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Table 1 Clinical and pathological data
Patient details Cutaneous lesions
Code Age/sex Graft Sun Aza/ CLIN BC IEC SCC IEC + Susc. Anogenital or
(M/F) (years) CyA VW Ker. SCC aggressiveles.
Patients with a graft life of> 15years
16 55 M 19 Mod Aza W Km
20 40 F 22 Low Aza W KmE
23 61 F 25 Mod Aza W Km
34 49 M 28 High Aza W Km
54 57 M 17 High Aza W Km
82 39 F 16 Low Aza W Km
3 43 M 20 Low Aza W Km
12 60 F 17 Low Aza W Km
21 63 M 25 High Aza W Km
30 57 F 16 Low Aza W Km
46 45 M 18 High Aza W Km
49 50 F 28 Low Aza W Km
51 40M 21 Low Az+C W Km
57 52 M 17 Mod Aza W Km
60 44 F 17 Low Aza W Km
61 59 F 16 Low CyA W K
80 62 M 19 Low Aza W K
1 47 M 17 Mod Aza W K
7 34 F 16 Low Aza W
22 38 F 16 Low Aza W K
41 47 M 23 Low Aza W K
70 52 M 17 Mod Aza W K
71 43 M 16 Mod Aza W -
72 58 M 16 High Aza W -
73 38M 17 Mod Aza W -
74 43M 17 Low Aza W -
75 42 M 20 Low Aza W -
76 41 M 22 Low Aza
77 60 M 21 Low Aza W K
78 35 F 21 Low Aza W
83 43 F 28 Low Az + C W K
Patients exhibiting keratoses, intraepidermal carcinomas orsquamous cellcarcinomas
26 54 M 10 High Aza W Km
27 67 M 8 High CyA - Km
64 57 M 9 High Aza W Km
2 67 F 15 Low Aza W Km
4 68 M 11 Low Aza W Km
5 43 F 10 Low Aza W Km
11 35 F 11 Low Aza W K
6 59 M 4 Mod CyA W Km
9 47 M 14 Mod Aza W K
56 63 M 11 Mod Aza W K
42 50 M 14 High Aza W
84 69 M 5 High Aza - K
85 68 F 1 UK CyA - K
86 58 M 5 Mod CyA W -
87 65 M 7 Mod CyA - K
88 68 M 9 High CyA W K
8 59 M 8 Mod CyA - Km
13 59 M 7 High CyA W K
14 60 M 6 Low CyA W -
18 59M 1oC Mod C+Az W Km
19 59 F 3 M/Hi CyA - Km
35 45 F 14 Low Aza W Km
39 59 M 9 C UK CyA - Km
40 69 M 15 High Aza W Km
44 49 F 15 Low Aza W KmE
48 51 M 6 High CyA W -
50 66 M 6 High Aza - Km
52 61 M 11 High Aza - Kml
53 38 M 8 High CyA W -
55 67 M 13 High Aza W Km
58 78 M 11 High Aza - Km
59 71 M 3 Mod CyA - -
62 63 M 15 Mod Aza W Km
31 30 F 13 Mod Aza W K
33 31 F 11 Low Aza - K
10 31 M 10 Low Az+C W K
17 44 M 14 Mod Aza W
81 54 M 12 High Aza W K
9
4
10
10
2
3
with a graftlife of 15 years
6
3
1 4
1
1
lPr
1
1
1
1
2
1
1
PPr
1
5
1
2
3 1
1 1
Accumulated lesions oftransplant recipients up to the end of 1994. Sex: M/F = Male/Female. Graft C, cardiac allograft recipient; all others are renal allograft recipients. Sun
exposure ratings: low, very little; mod, outdoor leisure activities; high, outdoor occupation of more than 3 months or lived in a tropical climate; M/Hi, mod to high rating; UK,
unknown. Immunosuppressants: Aza, azathioprine; CyA, cyclosporin A; C + Az, both CyA and Aza. CLIN, clinical observations (over long term follow-up) of cutaneous lesions (not
always biopsied); VW, viral warts; W, multiple warts; Ker., keratoses; K, 1-3 keratoses; Km, multiple keratoses (more than 3); E, epidermodysplasia verruciformis-like plaque; I,
intraepidermal carcinoma diagnosed clinically without histology. Histological diagnosis: BC, basal cell carcinoma; IEC, intraepidermal carcinoma; SCC, squamous cell carcinoma;
IEC + SCC, combined total of cutaneous malignancies including intraepidermal carcinomas and squamous cell carcinomas. Susc., susceptibility to development of cutaneous
malignancy; high susceptibility defined histopathologially as 24 IEC/SCC; Int., intermediate susceptibility defined as 1-3 IEC/SCC or >3 keratoses (including moderate or severe
dysplasia within keratoses); Low, low susceptibility defined as non-dysplastic warts or 1-3 keratoses (showing mild to moderate dysplasia), including clinically observed, non-
biopsied keratoses. Anogenital or Aggressive les., anogenital or aggressive cutaneous lesions; patient 20 had extensive carcinoma in situ (ECis) with CIN3 of cervix, VIN3 of vulva,
AIN3 of anal canal and also developed an invasive squamous cell carcinoma of anal canal [SCC-A] that metastasized; patient 23 had extensive carcinoma in situ (ECis) with CIN3
of cervix and VIN3 of vulva that developed into an invasive squamous cell carcinoma of vulva [SCC-V]; patient 34 developed multiple and confluent squamous cell carcinomas of
the scalp with aggressive invasion of scalp muscle and skull (Aggr. SCC-S); patient 82 developed CIN3 and squamous cell carcinoma of the vulva and anus/perineum (CIN3 +
SCC-VA); patient 22 developed CIN 1 of the cervix. Patient 2 had extensive carcinoma in situ (ECis) with CIN3 of cervix, VAIN3 of vagina and VIN3 of vulva. Patient 48 appears to
have an intermediate susceptibility of special type [Int. (S)], developing five BCCs but no IECs or SCCs; patient 5 developed CIN 2 of the cervix; patient 11 developed CIN2 of
cervix and VIN1 of vulva; and patients 19 and 33 developed CIN 1. 1 Pr, 1 prior lesion occurring before transplantation.
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Soler et al, 1992; Stark et al, 1994a). Uncharacterized HPV types
have been found in benign and malignant skin tumours using either
degenerate PCR primers (Shamanin et al, 1994), multiple comple-
mentary sets of consensus PCR primers (Tieben et al, 1994) or
nested PCR assays (Berkhout et al, 1995). The nested PCR
approach detected HPV in 81% SCCs from RARs, including a
wide spectrum ofknown and novel EV types ofHPV (Berkhout et
al, 1995). It appears that,as HPV diagnostic technology for abroad
spectrum of HPV types has improved, the reported prevalence of
HPV DNA in SCCs from RARs has crept upwards and currently
stands at around 80%. Here, we present data from a clinicopatho-
logical survey of RARs in south-east Scotland. This showed a
widely disparate susceptibility to cutaneous malignancy among
RARs, with evidence of concomitant variation in HPV DNA
prevalence in their skin neoplasms. This suggests an important
source ofbias that may affect small studies and provides an expla-
nation for the reported variation in HPV DNA prevalence and the
wide range of viral types in other studies. Significantly, high
susceptibility for cutaneous malignancy may represent an early
clinical marker for increased risk of development of potentially
lethal anogenital or aggressive cutaneous malignancy.
METHODS
Patients
Sixty-nine RARs and 53 immunocompetent patients (ICPs) were
investigated. RARs received transplants between 1965 and 1994.
Before 1984, prednisolone and azathioprine were the main
immunosuppressive drugs used, but thereafter most patients
received prednisolone and cyclosporin A. Immunocompetent
patients all presented to the Dermatology Department in
Edinburgh Royal Infirmary, UK, for treatment of viral warts or
skin tumours. Most of these patients were elderly with lesions on
sun-exposed sites.
specific HPV types 1, 2, 5, 8, 6b, 11, 16 and 18 (Arends et al,
1991; Stark et al, 1994a).
Histopathology
The skin lesions were classified as follows: viral warts (VWs)
exhibited symmetry, papilliferous architecture and koilocytic
change; verrucous keratoses (VKs) displayed the architecture of
warts but lacked definitive cytological features of viral infection;
and actinic keratoses (AKs) showed basal budding and basal
atypia (degrees of dysplasia were assessed in both types of
keratosis); however, actinic keratoses and verrucous keratoses
were combined into a single group ofkeratoses (Ker.) for analysis
of data in this study. Intraepidermal carcinoma (IEC) showed
eitherfull-thickness dysplasia or severe dysplasia and acantholysis
of the basal layer; invasive squamous cell carcinoma (SCC)
showed definite dermal invasion (Blessing et al, 1989).
Immunocytochemical and mutational analysis of p53
Immunocytochemistry was performed on 3-jim sections ofPLPD-
and formalin-fixed tissue, using the mouse anti p53 monoclonal
antibodies MAb Do-7 (Vojtesek et al, 1992) and PAb 1801 (Banks
et al, 1986) and a standard ABC horseradish peroxidase (HRP)
technique (Dako, High Wycombe, Bucks, UK) as previously
described (Purdie et al, 1991; Stark et al, 1994b). Formalin-fixed
tissue was treated with MAb Do-7 (1:100 dilution, overnight incu-
bation) only, whereas PLPD-fixed material was treated with MAb
Do-7 and PAb 1801 (1:100 dilution, 1-h incubation). Single-strand
conformational polymorphism (SSCP) analysis for mutations in
exons 5-8 of the p53 gene was performed on selected cases as
previously described (Stark et al, 1994b).
RESULTS
Clinicopathological survey of cutaneous lesions in
Tissue collection renal allograft recipients
Biopsy samples were bisected longitudinally, half was placed
immediately in PLPD (periodate lysine paraformaldehyde dichro-
mate) (Holgate et al, 1986) or 10% formalin and fixed for 24 h at
4°C before paraffin embedding. Histological assessment and
immunohistochemistry were carried out on sections prepared from
paraffin-embedded material. The other half were snap frozen in
liquid nitrogen and stored at - 70°C to await DNA extraction and
virological investigation.
DNA extraction and HPV detection
Frozen tissue was minced in lysis buffer (50 mM Tris, 50 mM
EDTA, 100 mm sodium chloride, 5 mM DTT, 1% sodium dodecyl
sulphate (SDS), 1.5 mg ml proteinase K) then incubated at 37°C
overnight; DNA extraction was carried out using a standard
phenol-chloroform extraction technique (Sambrook et al, 1989).
Two methods were used to screen for the presence of HPV DNA
(Stark et al, 1994a). Low-stringency Southern hybridization
analysis, using mixed HPV probes at low hybridization (Tm
- 40°C) and washing stringency (Tm -35°C), was used to detect a
range ofcommon cutaneous and epidermodysplasia verruciformis
(EV)-related types, including HPV types 1-20. Highly sensitive
polymerase chain reaction (PCR) assays were used to detect
We report a survey of RARs from the south-east ofScotland, who
have been monitored dermatologically over the past 15 years to
facilitate early detection of infective, premalignant or malignant
cutaneous lesions. Records have been kept of all skin lesions
developing since transplantation, and suspicious lesions have been
biopsied. Data have been collated (Table 1) for a group of69 trans-
plant patients, of whom 34 developed cutaneous malignancies.
Eight RARs were highly susceptible to the development ofmalig-
nant squamous tumours ofthe skin - defined clinicopathologically
as four or more IECs or SCCs. These high-susceptibility RARs
developed 5-37 cutaneous malignancies (IECs and SCCs) each,
with a median of 14 per patient. Forty-two RARs showed an inter-
mediate susceptibility to cutaneous malignancy, defined as 1-3
IECs or SCCs or >3 keratoses, both actinic and verrucous,
including those with moderate or severe epidermal dysplasia.
Intermediate susceptibility RARs developed a median ofone cuta-
neous malignancy each. Nineteen RARs showed a low suscepti-
bility to cutaneous malignancy defined as no IECs, no SCCs and
.3 keratoses (showing only mild or moderate dysplasia if biop-
sied) over a period of at least 10 years since transplantation,
despite developing multiple warts in some cases (Table 1).
Thirty-one RARs had graft lives of greater than 15 years. A
comparison of skin tumours from these patients with those from
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Table 2 HPV-positive lesions from RAR
Patient
code
16
20
23
34
54
26
Susceptibility Histology
High
High
High
High
High
High
64 High
8 Int.
18
40
50
59
Int.
Int.
Int.
Int.
SCC
SCC
IEC
SCC
SCC
SCC
SCC
IEC
IEC
IEC
Ker.
SCC
IEC
IEC
SCC
SCC
SCC
IEC
IEC
Ker.
Ker.
Ker.
Ker.
Ker.
SCC
SCC
SCC
SCC
IEC
Ker.
SCC
IEC
Ker.
IEC
Ker.
Ker.
Ker.
IEC
Ker.
Ker.
IEC
Southern
hybridization
Pos(2)
Pos(UK)
Neg
Neg
Neg
Neg
Pos(UK)
Pos(UK)
Pos(5)
Pos(3)
ND
Pos(UK)
Pos(UK)
Neg
Pos(UK)
Pos(UK)
Pos(UK)
Neg
Pos(UK)
Neg
Neg
Neg
Pos(UK)
Neg
Pos(3)
Pos(UK)
Pos(UK)
Pos(1)
Pos(UK)
Pos(UK)
Pos(UK)
Pos(UK)
Pos(UK)
Pos(UK)
Pos(UK)
Pos(UK)
Pos(10)
Neg
Neg
Pos(UK)
Pos(UK)
PCR
2
Neg
16
6
16
2
Neg
Neg
5
Neg
5
Neg
Neg
16
Neg
Neg
Neg
2
Neg
5
1
Neg
2
Neg
Neg
Neg
1
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
2
16
Neg
Neg
60
50
Z 30
10
0~
Ker. IEC SCC
* RAR-HS B RAR-ILS LI ICP
Figure 1 HPV DNA prevalence in seven renal allograft recipients with high
susceptibility to cutaneous malignancies (U, RAR-HS) from which lesional
DNA was available for HPV DNA detection using both Southern hybridization
analysis and PCR. These are compared with 23 intermediate- or low-
susceptibility renal allograft recipients (1, RAR-ILS) and 53
immunocompetent patient controls (E, ICP) in three groups of cutaneous
neoplasms collected between 1989 and 1993, including keratoses (Ker.),
intraepidermal carcinomas (IEC) and squamous cell carcinomas (SCC)
Seven high-susceptibility patients received immunosuppressive
therapy based primarily on azathioprine, and one received
cyclosporin A, but this reflected the availability of immunosup-
pressive drugs at the time of transplantation (cyclosporin A was
introduced in 1984/85). Insufficient time has elapsed for valid
comparisons to be made between patients receiving azathioprine
and those treated with cyclosporin A, although no significant
differences were found between the two regimens at 4 years
(Bunney et al, 1990). Furthermore,drug doses have been modified
over this extended study period, as has advice given to patients
regarding protection against sun exposure. The ranges ofpatients'
ages and sun-exposure ratings between the different susceptibility
groups overlap to such an extent that, given the small numbers of
patients involved, no definite pattern ofvariation emerges.
Int., intermediate; SCC, squamous cell carcinoma; IEC, intraepidermal
carcinoma; Ker., keratosis; pos(2), positive (HPV type 2); pos(UK), positive
(unknown HPV type); neg, negative.
38 RARs with a graft life of<15 years revealed no apparent differ-
ences in the prevalences of HPV DNA (Table 2). The group of
patients with graft lives of >15 years included five high-suscepti-
bility patients. The remaining three high-susceptibility patients had
graft lives of 8-10 years. The median graft lives for the three
patient groups were similar, as were their median ages (Tables 1
and 3). Despite the small numbers ofpatients concerned, these data
suggest that long graft life is not the only determinant of the high-
susceptibility phenotype, although the passage of time appears to
be required for its expression. Thus, it is possible that some of the
currently regarded 'intermediate-susceptibility' patients with short
graft lives may eventually go on to develop large numbers of IECs
or SCCs when sufficient time has elapsed to allow expression of
the high-susceptibility phenotype. However, 14 out of 19 low-
susceptibility patients had grafts of > 15 years' duration and thus
appear to have a low risk ofcutaneous malignancy that is stable.
HPV prevalence and patient susceptibility
To investigate HPV DNA prevalence, 159 cutaneous biopsies were
collected during the period 1989-93 from a sample of the survey
group that included 19 women and 33 men. Histopathological
analysis showed 28 viral warts,48 keratoses (combined actinic and
verrucous), 35 IECs, 41 SCCs and seven basal cell carcinomas,
diagnosed by previously described criteria (Blessing et al, 1989).
The IECs and SCCs examined were collected from 18 RARs.
Control samples were collected over the same period and included
103 biopsies from immunocompetent patients (ICPs), including 48
with either IEC or SCC; these patients were, on average, 20 years
older (mean age 75 years) than RARs with similar lesions (mean
age 54 years). All of these lesions were subjected to HPV DNA
detection by both low-stringency Southern hybridization analysis,
capable ofdetecting almost all ofHPV types 1-20,and PCR assays
specific for HPV types 1, 2, 5, 8, 6b, 11, 16 and 18, as previously
described (Arends et al, 1991; Stark et al, 1994a). These analyses
showed a range ofdifferent HPV types within the spectrum ofskin
neoplasms, including several of unknown HPV type detected by
low-stringency Southern hybridization analysis, but no specific
pattern or combination of HPV types in any one lesion (Table 2).
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Table 3 Characteristics of the 3 susceptibility groups
Malignant histology
IEC + SCC
Susceptibility No. of patients Graft No. of patients (%)
age range, life range Total with anogenital
median median Range (median no. of or aggressive
(years) (years) lesions per case) skin lesions
High 8 8-28,18 5-37 131 (14) 3 (38)
26-61, 54
Intermediate 42 1-28, 11 0-3 35 (1) 2 (5)
35-78, 59
Low 19 10-28,17 0 0(0) 0 (0)
30-60, 43
Susceptibility, susceptibility to development of cutaneous malignancy, high susceptibility defined histopathologically as .4 IEC/SCC; intermediate susceptibility
defined as 1-3 IEC/SCC or > 3 keratoses (including those with moderate or severe dysplasia within keratoses); low, low susceptibility defined as non-dysplastic
warts or 1-3 keratoses (showing mild/moderate dysplasia), including clinically observed, non-biopsied keratoses with no IECs and no SCCs over a period of at
least 10 years after transplantation. Malignant histology (lesions up to the end of 1994 included): IEC + SCC, combined total of cutaneous malignancies
including intraepidermal carcinomas (IEC) and squamous cell carcinomas (SCC). Anogenital or aggressive skin lesions, see text for details.
The overall prevalences of HPV DNA are shown in Figure 1
for seven high-susceptibility patients, 23 intermediate- or low-
susceptibility patients (these two groups were combined because of
small specimen numbers ofkeratoses foranalysis) and 53 immuno-
competent patient controls. HPV DNA prevalence was 50% in
keratoses (8/16), 45% in IECs (10/22) and 56% in SCCs (15/27)
from the high-susceptibility RARs, and these were greater than
those from either intermediate- or low-susceptibility RARs - 36%
in keratoses (5/14 from both intermediate- and low-susceptibility
RARs), 33% in IECs (3/9 from intermediate-susceptibility RARs)
and 0% in SCCs (0/2 from intermediate-susceptibility RARs) and
were also greater than those seen in immunocompetent patients:
15% in keratoses (2/13), 20% in IECs (5/25) and 27% in SCCs
(4/15). Statistical comparisons using the chi-squared test showed
significant differences only for HPV DNA prevalence in keratoses
from the high-susceptibility subset compared with that in immuno-
competent patients' keratoses (P<0.05), although an interesting,
but not statistically significant, trend was seen in the comparison
of the differences between HPV prevalences in the three groups
of SCCs (high-susceptibility subset, intermediate-susceptibility
subset and immunocompetent patients) (P=0.0875); the small
numbers of cases limited the power ofthis analysis. There may be
some under-reporting ofHPV prevalence using this combination of
low-stringency Southern hybridization analysis and specific PCR
assays as only 9/14 viral warts from RARs were shown to contain
HPV DNA using these methods, although this did increase to
14/19 (74%) if viral warts from immunocompetent patients were
included.
Accumulation of p53 protein in skin neoplasms
Accumulation ofthe p53 protein, a tumour suppressor involved in
the response to DNA damage, was analysed in a large subset of
these specimens from different susceptibility groups. One hundred
and twenty-eight biopsies ofskin tumours from RARs and 75 from
ICPs were screened for both p53 immunoreactivity and the pres-
ence ofHPV DNA (Stark et al, 1994b). Because ofthe limitations
of p53 immunostaining, single-strand conformational polymor-
phism (SSCP) analysis ofexons 5 to 8 ofthep53 gene was used in
28 malignancies (IECs and SCCs) and detected p53 mutations in
5/9 (56%) lesions with widespread p53 immunostaining (>50% of
tumour cells), 1/6 (17%) lesions with p53 staining occurring in
10-50% ofcells and none when <10% cells were stained (Stark et
al, 1994b). No clear relationship was observed between the pres-
ence or extent of accumulated p53 protein or p53 mutations and
either presence ofHPV DNA or patient susceptibility. Thus, these
dataexcluded p53 accumulation as a useful pathological markerof
the high-susceptibility phenotype.
Anogenital neoplasia and patient susceptibility
A statistically significant difference was observed in the occurrence
of potentially life-threatening multiple anogenital tract neoplasms
or aggressive cutaneous malignancy in 38% (3/8) high-suscepti-
bility RARs compared with 5% (2/42) intermediate-susceptibility
RARs (P=0.005, chi-squared test). There were only two women
among the eight high-susceptibility RARs and both developed
extensive anogenital carcinoma in situ (two or more of CIN 3 of
cervix, VAIN 3 ofvagina, VIN 3 ofvulva and AIN 3 ofanal canal),
together with an invasive squamous cell carcinoma ofeither vulva,
perineum or anal canal (one patient died of metastatic anogenital
carcinoma and one is still alive), whereas only 2 of 13 (15%)
women in the intermediate-susceptibility RARs developed in situ
carcinoma or invasive SCCs of the anogenital region (one patient
died of metastatic anogenital carcinoma and one died of a cere-
brovascular accident) (Table 1). A male high-susceptibility RAR
developed lethal, highly aggressive, spindle cell cutaneous SCCs
(multiple and confluent SCCs of scalp with aggressive local inva-
sion into scalp muscle, skull and dura mater). Two intermediate-
susceptibility RARs developed CIN2, one with VINI also. No
high-grade anogenital lesions were found in the low-susceptibility
patients. Two low- and one intermediate-susceptibility patients
developed CINI. HPV DNA prevalence was not assessed in these
lesions because fresh samples were not available. These data are
consistent with previous findings of a higher prevalence of CIN in
female RARs than in ICP controls, with increased detection of
'high risk' HPV 16 and 18 in CIN lesions and subclinical HPV
infections from RARs than controls (Alloub et al, 1989; Kelly et al,
1991) and also with a higher risk of anal HPV infection and anal
neoplasia in RARs than controls (Ogunbiyi et al, 1994).
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DISCUSSION
Despite the relatively small number of cases in the susceptibility
groups, the overall pattern of data from this clinicopathological
survey suggests that some RARs may have either an increased
susceptibility to persistent HPV infection, with an increased risk of
development of multiple malignancies of the skin and anogenital
tract, or some other mechanism of increased susceptibility to cuta-
neous and anogenital malignancy. In contrast, those RARs with a
low susceptibility to skin malignancies also have a very low inci-
dence of anogenital neoplasia, observed over long periods of
follow-up, which may relate to a low level ofcarriage ofHPV.
There are several possible reasons for a high susceptibility to
HPV-associated neoplasia, including effects of certain combina-
tions of MHC molecules that may modulate the immune response
to HPV, either to most HPV types or to specific HPV types (Wank
and Tomssen, 1991; Bouwes-Bavinck et al, 1993; Ellis et al, 1995),
genetically determined immunosuppressive effects ofUV radiation
acting locally (Yoshikawa et al, 1990), variations in the response of
the immune system to immunosuppressants and genetically deter-
mined differences in susceptibility to cutaneous malignancy per se.
Alternatively, there may be abnormal interactions between host
cells and HPV genomes which influence their replication and
expression, and this may lead to differences in the efficiency of
intracellular control of HPV activity (zur Hausen, 1994, 1995).
Variations in HPV activity may be important in modulating the
levels of HPV-induced cellular proliferation or apoptosis (Arends
et al, 1995), allowing HPVs to act as tumour promoters as previ-
ously suggested by zur Hausen (1986). In this way, HPVs may
drive neoplastic progression by forcing cell replication or by
suppressing apoptosis, which in turn may fix DNA mutations
induced by UV radiation or other mutagens. Hence, in high- or
intermediate-susceptibility patients, it is possible that increased
susceptibility to HPV infection or reduced intracellular control of
viral activity may allow HPVs to be more active promoters of
carcinogenesis of the squamous epithelium of both skin and
anogenital region. In such individuals, many different HPV types
may have a common promoter-like effect, explaining the lack ofan
HPV type-specific relationship with RAR-associated skin cancer.
Variations in both the HPV types involved and patient suscepti-
bility contribute to a complex situation in which it is difficult to
determine the true prevalence ofa wide range ofHPV types in skin
tumours in immunosuppressed transplant recipients. The difficulty
is compounded ifsmall numbers ofcases are studied with possible
distortions of the ratios of patients with high, intermediate or low
susceptibility or if insufficiently broad-spectrum HPV type detec-
tion techniques are used. This may be particularly important as
RARs appear to harbour a high proportion of unusual HPV types
in their skin tumours (Shaminin et al, 1994, 1996; Tieben et al,
1994, 1995), and this seems to be reflected in the significant
number of lesions containing HPV DNA of unknown type seen in
this study. These limitations are relevant to the design and data
interpretation of all investigations into the risk factors involved in
immunosuppression-associated neoplasia.
This study emphasizes the need for frequent screening for skin
tumours in transplant recipients, and this need for surveillance is
recognized by othergroups (Leigh and Glover, 1995; London et al,
1995). In particular, these data emphasize the clinical importance
of screening for potentially lethal anogenital neoplasms in high-
susceptibility RARs. The intermediate-susceptibility RARs are at
a lower risk of anogenital malignancy, but for the individual
patient this is a significant risk nevertheless. Furthermore, a
proportion of intermediate-susceptibility RARs may progress to
the high-susceptibility subset in time.
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